Combined Prolonged Exposure and Pramipexole Treatment for Patients with PTSD and Depression
Combined Prolonged Exposure and Pramipexole Treatment for Patients with PTSD and Depression
Sponsor: New York State Psychiatric Institute
Enrolling: Male and Female Patients
Clinic Visits: 13
IRB Number: 7692
U.S. Govt. ID: NCT03765138
Contact: Shay Arnon: 6467748106 / shay.arnon@nyspi.columbia.edu
Additional Study Information: Approximately half of the individuals with Post-traumatic Stress Disorder (PTSD) present with major depressive disorder (MDD). Compared to PTSD alone, patients with comorbid PTSD-MDD demonstrate greater distress and poorer treatment outcome. The goal of this pilot study is to collect preliminary data on the feasibility, safety, and initial efficacy of an integrated therapeutic approach of a combination treatment with PE and Pramipexole, a dopamine agonist, in treating patients suffering with PTSD and Depression. This study includes pre- and post- treatment research MRI Scans.
This study is closed
Investigator
Yuval Neria, PhD
Do You Qualify?
Are you between the ages of 18 and 60? Yes No
Are you currently on psychotropic medication (i.e antidepressants)? Yes No
Have you ever experienced a traumatic event, such as a sexual or physical assault, natural disaster, or combat? Yes No
Do you experience nightmares of thinking about the traumatic event when you do not want to? Yes No
do you experience feeling guilty or down on yourself? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Shay Arnon
shay.arnon@nyspi.columbia.edu
6467748106